Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development expenses	$ 11,643	$ 5,825
General and administrative expenses	7,046	2,418
Total operating expenses	18,689	8,243
Loss from operations	(18,689)	(8,243)
Other income and expenses:
Grant income	4,915	1,589
Fair value adjustment for preferred stock tranche rights liability		1,265
Research and development tax credits		184
Other income (expense), net	240	(42)
Net loss	(13,534)	(5,247)
Cumulative dividends on Series A preferred stock		(107)
Accretion of redeemable convertible preferred stock to redemption value		(1,195)
Net loss attributable to common stockholders	$ (13,534)	$ (6,549)
Basic and diluted net loss per common share	$ (0.39)	$ (25.53)
Weighted-average common shares outstanding—basic and diluted	35,086,662	256,548
Net loss	$ (13,534)	$ (5,247)
Foreign currency translation adjustments	(305)	(317)
Comprehensive loss	$ (13,839)	(5,564)
Series A Preferred Stock
Other income and expenses:
Accretion of redeemable convertible preferred stock to redemption value		$ (1,195)